PDE4 inhibitor (apremilast) in pemphigoid.

Phase 1

• Conditions: Pemphigoid; Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

• Registration Number: EUCTR2018-002564-10-NL
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-23
• Last Update Posted: 30 June 2019

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

Adult (= 18 years of age) male or female patients with recently diagnosed mild to moderate localized or generalized cutaneous pemphigoid, or patients that were in complete remission without treatment that have a mild to moderate flare-up of the disease.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 5
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5

Exclusion Criteria

Women of childbearing potential without contraception; women who are pregnant or planning to become pregnant or who are lactating; patients that use systemic immunosuppressive medication; any condition which would make the patient unsuitable for treatment, or requires steroid use.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified